Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells

Journal of Allergy and Clinical Immunology

Volumn 98, Issue 2, 1996, Pages 389-399

  Sperr, Wolfgang R ^a   Agis, Hermine ^a   Czerwenka, Klaus ^b   Virgolini, Irene ^b   Bank, Hans C ^a   Müller, Michael R ^b   Zsebo, Krisztina ^c   Lechner, Klaus ^a   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c AMGEN INC   (United States)

Author keywords

c kit; histamine; IgE; Mast cells; stem cell factor; tryptase

Indexed keywords

CYCLIC AMP; CYCLOSPORIN A; CYCLOSPORIN H; HISTAMINE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT INTERLEUKIN 3; RECOMBINANT INTERLEUKIN 4; RECOMBINANT STEM CELL FACTOR; TACROLIMUS;

ARTICLE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; HISTAMINE RELEASE; HUMAN; HUMAN CELL; MAST CELL; PRIORITY JOURNAL;

EID: 0029791054     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(96)70163-X     Document Type: Article

References (58)

1. Ishizaka T, Ishizaka K. Activation of mast cells for mediator release through IgE receptors. Prog Allergy 1984;34:188-235.
2. Serafln WE, Austen KF. Mediators of immediate hypersensitivity reactions. N Engl J Med 1987:317:30-4.
3. Galli SJ. Biology of disease. New insights into "The riddle of the mast cells": microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest 1990;62:5-33.
4. Kitamura Y, Yokoyama M, Matsuda H, Ohno T, Mori KJ. Spleen colony forming cell as common precursor for tissue mast cells and granulocytes. Nature 1981;291:159-60.
5. Valent P, Spanblöchl E, Sperr WR, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor (SCF)/kit ligand (KL) in long term culture. Blood 1992;80:2237-45.
6. Mitsui H, Furitsu T, Dvorak AM, et al. Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc Natl Acad Sci USA 1993;90:735-40.
7. Anderson DM, Lyman SD, Baird A, et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 1990;63:235-43.
8. Flanagan JG, Chan DC, Leder P. Transmembrane form of the kit ligand growth factor is determined by alternative splicing and is missing in the Sld mutant. Cell 1991;64:1025-35.
9. Zsebo KM, Williams DE, Geissler EN, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990;63:213-24.
10. Bischoff SC, Dahinden CA. c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med 1992;175:237-44.
11. Columbo M, Horowitz EM, Botana LM, et al. The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE dependent mediator release from both skin mast cells and peripheral blood basophils. J Immunol 1992;149:599-08.
12. Sperr WR, Czerwenka K, Mundigler G, et al. Specific activation of human mast cells by the ligand for c-kit: comparison between lung, uterus and heart mast cells. Int Arch Allergy Immunol 1993;102:170-5.
13. Coleman JW, Holliday MR, Kimber I, Zsebo KM, Galli SJ. Regulation of mouse peritoneal mast cell secretory function by stem cell factor, IL-3 or IL-4 mouse mast cells SCF activation. J Immunol 1993;150:556-62.
14. Mayrhofer G, Gadd SJ, Spargo LDJ, Ashman LK. Specificity of a mouse monoclonal antibody raised against acute myeloid leukemia cells for mast cells in human mucosal and connective tissues. Immunol Cell Biol 1987;65:241-50.
15. Lerner NB, Nocka KH, Cole SR, et al. Monoclonal antibody YB8.B5 identifies the human c-kit protein product. Blood 1991;77:1876-83.
16. Sillaber C, Bevec D, Ashman LK, et al. IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol 1991;147:4224-8.
17. Huang E, Nocka K, Beier DR, et al. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990;63:225-33.
18. Ashman LK, Cambareri AC, To LB, Levinski RJ, Juttner CA. Expression of c-kit by normal human bone marrow cells. Blood 1991;78:30-7.
19. Borel JF, Feurer C, Gubler HU, Staehlin H. Biologic effects of cyclosporin-A: a new anti-lymphocytic agent. Agents Actions 1976;6:468-75.
20. Calne RY, Thiru S, MacMaster P, et al. Cyclosporin A in patients receiving renal allograft from cadaver donors. Lancet 1978;2:1323-32.
21. Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316:719-24.
22. Stiller CR, Dupre J, Gent M, et al. Effects of cyclosporin immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984;223:1362-5.
23. Shevach EM. The effects of cyclosporin A on the immune system. Annu Rev Immunol 1985;3:397-423.
24. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK-506. Immunol Today 1992;13:136-42.
25. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987;60:1256-65.
26. Sawada S, Suzuki C, Kawase Y, Takaku F. Novel immuno-suppressive agent, FK-506: in vitro effects on cloned T cell activation. J Immunol 1987;139:1797-803.
27. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK-506 for liver, kidney and pancreas transplantation. Lancet 1989;2:1000-4.
28. de Paulis A, Cirillo R, Ciccarelli A, de Crescenzo G, Oriente A, Marone G. Characterization of the anti-inflammatory effect of FK-506 on human mast cells. J Immunol 1991;147:4278-85.
29. + cells. J Immunol 1991;146:2374-81.
30. Stellato C, de Paulis A, Ciccarelli A, et al. Anti-inflammatory effects of cyclosporin A on human skin mast cells. J Invest Dermatol 1992;98:800-4.
31. 2 release from human lung mast cells by cyclosporin A. Int Arch Appl Immunol 1989;88:235-55.
32. Cirillo R, Triggiani M, Siri L, et al. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophylin. J Immunol 1990;144:3891-7.
33. 4 from human lung mast cells. Ricerca Clin Lab 1988;18:53-7.
34. Casolaro V, Spadaro G, Patella V, Marone G. In vivo characterization of anti-inflammatory effects of cyclosporin A on human basophils. J Immunol 1993;151:5563-73.
35. Kaufmann Y, Rosenberg SA. Blocking by cyclosporin of antigen-induced maturation and lymphokine secretion by cytotoxic T lymphocyte hybridomas. J Immunol 1984;38:148-54.
36. Krönke M, Leonard WL, Depper JM, et al. Cyclosporin A inhibits T cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 1984;81:5214-8.
37. Hess AD, Donnenberg AD, Tuschka PJ, Santos GW. V. Effect of cyclosporin A on human lymphocyte responses in vitro. Analysis of responding T lymphocyte subpopulation in primary MLR with monoclonal antibodies. J Immunol 1983;130:717-24.
38. Schulman ES, MacGlashan DW, Peters SP, Schleimer RP, Newball HH, Lichtenstein LM. Lung mast cells: purification and characterization. J Immunol 1982;129:2662-7.
39. Massey WA, Guo CB, Dvorak AM, et al. Human uterine mast cells: purification, characterization, ultra-structure and pharmacology. J Immunol 1991;147:1621-27.
40. Valent P, Ashman LK, Hinterberger W, et al Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunphenotypic relationship to mononuclear phagocytes. Blood 1989;73:1778-85.
41. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988;12:345-55.
42. Valent P, Besemer J, Muhm M, Majdic O, Lechner K, Bettelheim P. Interleukin 3 activates human blood basophils via high-affinity binding sites. Proc Natl Acad Sci USA 1989;86:5542-6.
43. Virgolini I, Li SR, Sillaber C, et al. Characterization of prostaglandin (PG) binding sites expressed on human basophils. Evidence for prostaglandin E1-, 12- and a D2-receptor. J Biol Chem 1992;267:12700-8.
44. Schwartz LB. Tryptase, a mediator of human mast cells. J Allergy Clin Immunol 1990;86:594-8.
45. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid dependent chronic severe asthma. Lancet 1992;339:324-8.
46. Hirai K, Morita YM, Misaki Y, et al. Modulation of human basophil histamine release by hemopoietic growth factors. J Immunol 1988;141:3958-64.
47. Schleimer RP, Derse CP, Friedmann B, et al. Regulation of basophil mediator release by cytokines. J Immunol 1989;143:1310-7.
48. Kurimoto Y, DeWeck AL, Dahinden CA. Interleukin-3 dependent mediator release in basophils triggered by C5a. J Exp Med 1989;170:467-79.
49. Valent P, Besemer J, Sillaber C, et al. Failure to detect interleukin-3 binding sites on human mast cells. J Immunol 1990;145:3432-7.
50. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984;226:544-7.
51. Takahashi N, Hayano T, Suzuki M. Peptidyl-prolyl-cistrans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 1989;337:473-5.
52. Fischer G, Whittman-Liebold B, Lang K, Kiefhaber T, Schmid FX. Cyclophilin and peptidyl-prolyl-cis-trans isomerase are probably identical proteins. Nature 1989;337:476-8.
53. Harding MW, Galat A, Uehling DE, Schreiber SL. A receptor for the immunosuppressant FK-506 is a cis-trans peptidyl prolyl isomerase. Nature 1989;341:758-60.
54. Siekierka JJ, Huang SHY, Poe M, Lin CS, Sugal SH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989;341:755-7.
55. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991;66:807-15.
56. Irani AA, Nilsson G, Ashman LK, Schwartz LB. Dexamethasone inhibits the development of mast cells from dispersed human fetal liver cells cultured in the presence of recombinant human stem cell factor. Immunology 1995;84:72-8.
57. Nilsson G, Miettinen U, Ishizaka T, Ashman LK, Irani AMA, Schwartz LB. Interleukin 4 inhibits the expression of kit and tryptase during stem cell factor dependent develop-ment of human mast cells from fetal liver cells. Blood 1994;84:1519-27.
58. Sillaber C, Sperr WR, Agis H, Spanblöchl E, Lechner K, Valent P. Inhibition of kit ligand induced differentiation of human mast cells by interleukin-3 and interleukin-4. Int Arch Allergy Immunol 1994;105:264-8.